Paul Hastings, Nkarta CEO and BIO chair

'Front and cen­ter': In­dus­try lead­ers call for re­sponse to Supreme Court abor­tion case draft

Biotech in­dus­try lead­ers want the drug de­vel­op­ment world to stand up and en­sure em­ploy­ees have ac­cess to abor­tions af­ter a draft rul­ing last week re­vealed the na­tion’s high­est court might over­turn a near­ly five-decade-old rul­ing, known by two names: Roe v. Wade.

“We have to make noise, for one thing, which is ef­fec­tive, but al­so en­cour­age peo­ple to take some sort of ac­tion,” Paul Hast­ings told End­points News. Last week, the Nkar­ta CEO and BIO chair called on his fel­low biotech com­pa­nies to help pay for trav­el ex­pens­es for em­ploy­ees in states hin­der­ing ac­cess to re­pro­duc­tive health.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.